Pfizer: granted mould infections drug rights from Basilea.
(CercleFinance.com) - Pfizer has been granted the exclusive commercialisation rights in Europe to a novel anti-fungal treatment for adult patients with diagnosed invasive aspergillosis and mucormycosis.
Under the terms of the agreement concluded with Switzerland's Basilea, Pfizer will have exclusive rights to distribute Cresemba in Austria, France, Germany, Italy and the United Kingdom, where it is currently available.
In addition, Pfizer will be responsible for additional Cresemba launches, predominantly in Europe, which are expected throughout 2017 and 2018.
The rights do not extend to the Nordic countries (Denmark, Finland, Norway, Sweden, or Iceland).
Invasive aspergillosis and mucormycosis are considered to be two serious infections associated with high morbidity and mortality among immunocompromised patients.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Under the terms of the agreement concluded with Switzerland's Basilea, Pfizer will have exclusive rights to distribute Cresemba in Austria, France, Germany, Italy and the United Kingdom, where it is currently available.
In addition, Pfizer will be responsible for additional Cresemba launches, predominantly in Europe, which are expected throughout 2017 and 2018.
The rights do not extend to the Nordic countries (Denmark, Finland, Norway, Sweden, or Iceland).
Invasive aspergillosis and mucormycosis are considered to be two serious infections associated with high morbidity and mortality among immunocompromised patients.
Copyright (c) 2017 CercleFinance.com. All rights reserved.